Bionx launches bioresorbable implant:
This article was originally published in Clinica
Executive Summary
Bionx Implants has launched its 4.5mm cannulated SmartScrew system. The product is a bioresorbable implant for maintaining alignment of cancellous bone fractures of the malleoulus of the ankle. The company believes there are 130,000 ankle fractures annually in the US that could be treated with resorbable fracture fixation. Blue Bell, Pennsylvania-based Bionx develops and manufactures self-reinforced, resorbable polymer implants for use in orthopaedic and craniofacial surgery as well as urological applications.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.